← All indications
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
Subtype terms (3)
More specific conditions that are subtypes of Aggression in the MeSH hierarchy.
Drugs by status
Approved for this indication (2)
Phase 4 trials (7)
Phase 3 trials (6)
Phase 2 trials (5)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (31)
- Shire
- AstraZeneca
- Novartis
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- Armenteros, Jorge L., M.D., P.A.
- Facultad Nacional de Salud Publica
- Kocaeli University
- Marmara University
- Monash University
- New York University
- Northwell Health
- Shandong Provincial Hospital
- University of Nottingham
- University of Toronto
- Utrecht University
- Columbia University
- Stony Brook University
- University of Campinas
- Faculdade de Odontologia de Piracicaba
- Al Azhar University
- Croix-Rousse Hospital, Lyon
- Janssen Pharmaceutica NV
- Winthrop University
- Jorge L. Armenteros, M.D., P.A.
- FPC De Kijvelanden
- Washington University in St. Louis
- Erasmus University Rotterdam
- Lundbeck
- +1 more
Organization Involved with Phase 3 Indications (26)
- Amgen
- Merckle
- Pfizer
- CTI BioPharma
- Teva
- University of Pennsylvania
- Boca Raton Regional Hospital
- Drexel University
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Deutsche Krebshilfe e.V.
- Hoosier Cancer Research Network
- Sykehuset Innlandet HF
- University of Heidelberg
- University of Ottawa
- Joint Child Health Project, Mauritius
- Saarland University
- Tel Aviv University
- City University of Hong Kong
- City University of New York
- The University of Hong Kong
- University of Duisburg-Essen
- Supernus Pharmaceuticals
- Sao Paulo State University
- Ben Gurion University
- Christian Medical College, Vellore, India
- SpringWorks Therapeutics, Inc.
Organization Involved with Phase 2 Indications (76)
- Zeneus Pharma
- Acadia Pharmaceuticals
- Celgene
- Bristol-Myers Squibb
- Roche
- Immunomedics
- Merck
- Elan Pharmaceuticals
- Eli Lilly
- MedImmune
- Avanir
- GWT-TUD GmbH
- Mediti Pharma Inc.
- Mundipharma
- PharmaMar
- Transition Therapeutics
- PETHEMA Foundation
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- University of Pittsburgh
- Case Western Reserve University
- University of London
- Eastern Virginia Medical School
- Emory University
- Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
- University of Washington
- French Innovative Leukemia Organisation
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Gruppo Italiano Studio Linfomi
- +46 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (15)
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Arizona State University
- Swansea University
- University of Florida
- University of Iowa
- University of Medicine and Dentistry of New Jersey
- University of New Mexico
- Peking University
- University of Connecticut
- Icahn School of Medicine at Mount Sinai
- Leiden University
- Department of Veteran Affairs
- State of Pennsylvania
- The Institute for Rehabilitation and Research (TIRR) Foundation
- Department of Education